US 12,404,333 B2
Anti PD-L1 antibody and use thereof
Jianmin Fang, Shandong (CN); Jing Jiang, Shandong (CN); Shenjun Li, Shandong (CN); and Guorui Zhao, Shandong (CN)
Assigned to REMEGEN CO., LTD., Shandong (CN)
Appl. No. 17/312,884
Filed by REMEGEN CO., LTD., Shandong (CN)
PCT Filed Aug. 25, 2020, PCT No. PCT/CN2020/110935
§ 371(c)(1), (2) Date Jun. 10, 2021,
PCT Pub. No. WO2021/037007, PCT Pub. Date Mar. 4, 2021.
Claims priority of application No. 201910805440.7 (CN), filed on Aug. 29, 2019.
Prior Publication US 2022/0177590 A1, Jun. 9, 2022
Int. Cl. C12N 15/63 (2006.01); A61K 39/00 (2006.01); A61P 35/00 (2006.01); C07K 16/28 (2006.01); C12N 15/62 (2006.01)
CPC C07K 16/2827 (2013.01) [A61P 35/00 (2018.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); C12N 15/62 (2013.01); C12N 15/63 (2013.01); C12N 2510/00 (2013.01)] 12 Claims
 
1. An isolated anti-PD-L1 antibody or antigen-binding fragment thereof comprising a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region and the light chain variable region comprise the following CDRs:
(1) CDRs 1-3 of the heavy chain variable region comprising the amino acid sequences of SEQ ID NOs: 1-3 respectively, and the CDRs 1-3 of the light chain variable region comprising the amino acid sequences of SEQ ID NOs: 4-6 respectively; or
(2) CDRs 1-3 of the heavy chain variable region comprising the amino acid sequences of SEQ ID NOs: 7-9 respectively, and CDRs 1-3 of the light chain variable region comprising the amino acid sequences of SEQ ID NOs: 10-12 respectively; or
(3) CDRs 1-3 of the heavy chain variable region comprising the amino acid sequences of SEQ ID NOs: 13-15 respectively, and CDRs 1-3 of the light chain variable region comprising the amino acid sequences of SEQ ID NOs: 16-18 respectively; or
(4) CDRs 1-3 of the heavy chain variable region comprising the amino acid sequences of SEQ ID NOs: 19-21 respectively, and CDRs 1-3 of the light chain variable region comprising the amino acid sequences of SEQ ID NOs: 22-24 respectively; or
(5) CDRs 1-3 of the heavy chain variable region comprising the amino acid sequences of SEQ ID NOs: 25-27 respectively, and CDRs 1-3 of the light chain variable region comprising the amino acid sequences of SEQ ID NOs: 28-30 respectively.